oral Azacitidine as maintenance treatment. It is the first medication to extend survival by nearly 10 months, filling a long-standing gap in cancer treatment. With the advent of AZADINE, an injectable Azacitidine, in 2014, Intas opened doors for a new era in the treatment of MDS – myelodysplastic syndrome. Azadine-O represents yet another significant advancement in the treatment of Acute Myeloid Leukemia.
Professor Dr M. B. Agarwal, India’s top Haematologist, expressed his opinion about the launch of the drug. He said, “Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients.”
Intas Pharmaceuticals Ltd., headquartered in Ahmedabad, India, is a prominent vertically integrated pharmaceutical business with end-to-end capabilities in formulation development, production, and sales, as well as API backward integration. Intas employs over 18,000 people globally, sells its goods in over 85 countries, and has 14 production facilities around the world. The revenues of Intas group were USD 2.1 billion in the financial year 2020, with a compounded annual growth rate of more than 25% during the previous ten years.
